Systemic mastocytosis: 2023 update on diagnosis and management in adults
Expert Opin Emerg Drugs. 2023 Jun 6:1-13. doi: 10.1080/14728214.2023.2221028. Online ahead of print.ABSTRACTINTRODUCTION: Systemic mastocytosis (SM) is a complex and heterogeneous disease, characterized by the clonal accumulation of mast cells in one or more organs. In 2022 both the World Health Organization (WHO) and the International Consensus Classification (ICC) modified the diagnostic and classification criteria of SM. Moreover, the identification of new clinical and molecular variables has improved prognostic tools and led to increasingly individualized therapeutic strategies.AREAS COVERED: The aim of this review is ...
Source: Expert Opinion on Emerging Drugs - May 31, 2023 Category: Drugs & Pharmacology Authors: Alessandro Costa Emilia Scalzulli Ida Carmosino Marcello Capriata Claudia Ielo Chiara Masucci Mauro Passucci Maurizio Martelli Massimo Breccia Source Type: research
Systemic mastocytosis: 2023 update on diagnosis and management in adults
Expert Opin Emerg Drugs. 2023 May 31. doi: 10.1080/14728214.2023.2221028. Online ahead of print.ABSTRACTINTRODUCTION: Systemic mastocytosis (SM) is a complex and heterogeneous disease, characterized by the clonal accumulation of mast cells in one or more organs. In 2022 both the World Health Organization (WHO) and the International Consensus Classification (ICC) modified the diagnostic and classification criteria of SM. Moreover, the identification of new clinical and molecular variables has improved prognostic tools and led to increasingly individualized therapeutic strategies.AREAS COVERED: The aim of this review is to p...
Source: Expert Opinion on Emerging Drugs - May 31, 2023 Category: Drugs & Pharmacology Authors: Alessandro Costa Emilia Scalzulli Ida Carmosino Marcello Capriata Claudia Ielo Chiara Masucci Mauro Passucci Maurizio Martelli Massimo Breccia Source Type: research
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials
Expert Opin Emerg Drugs. 2023 Apr 25. doi: 10.1080/14728214.2023.2207819. Online ahead of print.ABSTRACTINTRODUCTION: Migraine is a leading cause of years lived with disability and preventive strategies represent a mainstay to reduce health-related disability and improve quality of life of migraine patients. Until a few years ago, migraine prevention was based on drugs developed for other clinical indications and relocated in the migraine therapeutic armamentarium, characterized by unfavourable tolerability profiles. The advent of monoclonal antibodies against Calcitonin Gene-Related Peptide (CGRP) and gepants, CGRP recept...
Source: Expert Opinion on Emerging Drugs - May 15, 2023 Category: Drugs & Pharmacology Authors: Marcello Silvestro Ilaria Orologio Mattia Siciliano Francesca Trojsi Alessandro Tessitore Gioacchino Tedeschi Antonio Russo Source Type: research
